Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor
Retrospective analysis shows allogeneic HSCT and tyrosine kinase inhibitors enhance outcomes in pediatric CML patients, suggesting a new approach to care.
Key Points
To evaluate the outcomes of pediatric patients with de novo chronic myeloid leukemia in blast phase receiving early stem cell transplantation and tyrosine kinase inhibitors.
Retrospective analysis of pediatric CML-BP patients receiving HSCT from May 2023 to March 2025.
Patients diagnosed according to WHO 2022 criteria; treatment included dasatinib or olverembatinib alongside HSCT.
Monitoring for minimal residual disease and bone marrow assessments post-transplant.